Close Menu

NEW YORK – New data from the SOLO-1 trial presented at a conference this week demonstrate that first-line maintenance treatment with the PARP inhibitor olaparib (AstraZeneca/Merck's Lynparza) results in a sustained progression-free survival benefit for patients with BRCA-mutated advanced ovarian cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.